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Objective To assess the frequency of obstructive sleep apnoea
among women with and without hypertensive disorders of
pregnancy.
Design Cohort study.
Setting Obstetric clinics at an academic medical centre.
Population Pregnant women with hypertensive disorders (chronic
hypertension, gestational hypertension, or pre-eclampsia) and
women who were normotensive.
Methods Women completed a questionnaire about habitual
snoring and underwent overnight ambulatory polysomnography.
Main outcome measures The presence and severity of obstructive
sleep apnoea.
Results Obstructive sleep apnoea was found among 21 of 51
women with hypertensive disorders (41%), but in only three of 16
women who were normotensive (19%, chi-square test, P = 0.05).
[Author correction added on 16 June 2014, after first online
publication: Results mentioned in the abstract were amended.]
Non-snoring women with hypertensive disorders typically had
mild obstructive sleep apnoea, but >25% of snoring women with
hypertensive disorders had moderate to severe obstructive sleep
apnoea. Among women with hypertensive disorders, the mean
apnoea/hypopnoea index was substantially higher in snorers than
in non-snorers (19.9  34.1 versus 3.4  3.1, P = 0.013), and the
oxyhaemoglobin saturation nadir was significantly lower
(86.4  6.6 versus 90.2  3.5, P = 0.021). Among women with
hypertensive disorders, after stratification by obesity, the pooled
relative risk for obstructive sleep apnoea in snoring women with
hypertension compared with non-snoring women with
hypertension was 2.0 (95% CI 1.4–2.8).
Conclusions Pregnant women with hypertension are at high risk
for unrecognised obstructive sleep apnoea. Although longitudinal
and intervention studies are urgently needed, given the known
relationship between obstructive sleep apnoea and hypertension
in the general population, it would seem pertinent that
hypertensive pregnant women who snore should be tested for
obstructive sleep apnoea, a condition believed to cause or
promote hypertension.
Keywords Hypertension, obstructive sleep apnoea, pregnancy,
snoring.
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Introduction
Hypertensive disorders affect approximately 10% of preg-
nancies and increase the risk for adverse outcomes.1 In
addition, they substantially increase healthcare costs.2 Of
particular concern is pre-eclampsia, characterised by
new-onset hypertension and proteinuria after 20 weeks of
gestation.3 Prompt recognition, evaluation, and manage-
ment are required to prevent end-organ damage. From a
public health perspective, it is alarming that the incidence
of pre-eclampsia has increased by almost one-third in the
past decade, and is responsible for over 60 000 maternal
deaths each year.4 Moreover, women with pre-eclampsia
are at increased risk of cardiovascular disease later in life.5,6
In the non-pregnant population, a key contributor to
hypertensive disease is obstructive sleep apnoea,7 a disorder
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characterised by nocturnal airway collapse, with the disrup-
tion of normal ventilation, hypoxaemia, and sleep
fragmentation. The prevalence of obstructive sleep apnoea
in women aged 30–39 years is approximately 6.5%, with
moderate or severe obstructive sleep apnoea affecting 1–
5%.8–10 The prevalence of obstructive sleep apnoea also
increases with increasing body mass index.11 Nonetheless, it
remains highly under-diagnosed: more than 90% of women
with obstructive sleep apnoea do not know that they have
it.12 Treatment of obstructive sleep apnoea, using the
gold-standard positive airway pressure, reduces cardiovas-
cular morbidity and mortality, with improvement in day-
time and nocturnal blood pressure.13,14
Accumulating evidence shows that habitual snoring, the
hallmark symptom of obstructive sleep apnoea, increases in
frequency during pregnancy,15–18 and affects up to
one-third of women by the third trimester.17,19 Although
the prevalence of objectively documented obstructive sleep
apnoea in pregnancy remains unknown, a recent study
found that 15% of obese pregnant women have obstructive
sleep apnoea in the first trimester.20 Importantly, most
studies that have queried pregnant women about snoring
or performed overnight polysomnography (sleep study)
demonstrate an association with gestational hypertension
and pre-eclampsia.15,17,19–24 In the largest prospective study
to date, we have recently shown that snoring, specifically
new-onset snoring, during pregnancy is independently
associated with gestational hypertension and pre-eclampsia,
even after accounting for other contributing factors.17
Moreover, a recent polysomnographic study of women
with and without gestational hypertension found a higher
frequency of obstructive sleep apnoea in women with gesta-
tional hypertension (53 versus 12%, P < 0.001).24
As treatment for obstructive sleep apnoea is readily avail-
able and can reduce blood pressure,13 confirmation of its
frequency during pregnancy and identification of ways to
screen for it should be a high priority. The goal of this study
was to investigate the frequency of unrecognised obstructive
sleep apnoea and symptoms that may help to identify it
among hypertensive pregnant women, as compared with
healthy pregnant women who were normotensive.
Methods
These data represent the initial analyses of a longitudinal
treatment intervention trial in hypertensive pregnancies.
Hypertensive pregnant women were recruited from
high-risk prenatal clinics or inpatient units within the Uni-
versity of Michigan between March 2009 and July 2013.
Women were eligible if they were ≥14 years of age and had
a clinical diagnosis of chronic hypertension, gestational
hypertension, or pre-eclampsia, as obtained from obstetric
notes in the medical records, and verified by medical coding
using the ninth revision of the International Classification
of Diseases (ICD-9).25 Women were eligible at any gesta-
tional age. For comparison, women who were normoten-
sive, without comorbidities, were recruited from prenatal
clinics in a parallel study using identical methods. Written
informed consent was obtained from all women. Approval
was obtained by the University of Michigan Institutional
Review Board (IRBMed).
Upon enrollment, women completed a questionnaire
about sleep and symptoms of obstructive sleep apnoea.
Participants were asked the following questions.
1 ‘How often do you snore?’ The response options offered
were: ‘Almost every night’; ‘Three or four times per
week’; ‘One or two times per week’; ‘One or two times
per month’; or ‘Never or almost never’. Habitual snoring
was considered present if women reported snoring
‘Three or four times per week’ or ‘Almost every night’.
2 ‘During this pregnancy have you stopped breathing or
gasped for air?’ The response options offered were:
‘Almost every night’; ‘Three or four times per week’;
‘One or two times per week’; ‘One or two times per
month’; or ‘Never or almost never.’
3 ‘If you have snored during this pregnancy, when did the
snoring begin?’, in order to identify the gestational tim-
ing of snoring onset to identify women who had chronic
symptoms prior to pregnancy. The response options
were: ‘Already snored before pregnancy’; ‘Snoring started
in the first trimester’; ‘Snoring started in the second tri-
mester’; or ‘Snoring started in the third trimester’.
In addition, all women underwent polysomnography
either at home or in the hospital (for women who were in-
patients) using a portable device (Medipalm, Braebon,
Ontario, Canada, or Embletta Gold, Embla, Bromfield, CO,
USA). A trained technologist visited all women, initiated
the monitoring, and returned on the following morning
to retrieve the equipment and download the data. The
following channels were recorded: six-channel electroen-
cephalogram (EEG); submental electromyogram; electro-oc-
ulogram; electrocardiogram; nasal and oral airflow
(thermistor, nasal pressure transducer); chest and abdomi-
nal respiratory movement, using respiratory inductance
plethysmography; oxygen saturation (SpO2); snoring
microphone; and body position sensor. All of the sleep
studies were manually scored by a single board-certified
sleep technician blinded to study group (maternal hyper-
tensive status), and were reviewed by a board-certified sleep
physician (AVS), who was also blinded to study group.
Scoring followed American Academy of Sleep Medicine rec-
ommendations.26 Sleep duration, based upon standard EEG
scoring, was available for n = 50 women (75%). Women
also had a parallel Watch-PAT study (peripheral arterial to-
nometry, a wrist-worn finger plethysmograph) at the same
time as the ambulatory polysomnography. The Watch-PAT
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is a well-validated measure of sleep that uses an inbuilt
actigraph to measure sleep duration.27–30 Thus, sleep dura-
tion was calculated from the Watch-PAT for those in
whom EEG was unavailable, generally because of technical
failures, which are common when full polysomnography is
attempted outside a laboratory setting.31,32 We have previ-
ously demonstrated the validity of Watch-PAT in preg-
nancy.33 Apnoea was defined by a drop in peak thermistor
excursion by >90% of the pre-event baseline, where at least
90% of the duration met the amplitude reduction criteria
for apnoea, with a duration of ≥10 seconds. Obstructive
apnoea was defined as apnoea with continued respiratory
effort. Hypopnoeas were scored if the nasal pressure signal
excursion dropped by >50% of baseline for ≥10 seconds
with ≥3% desaturation or with an arousal. The apnoea
hypopnoea index (AHI) was calculated as the number of
apnoeas and hypopnoeas per hour of total sleep time. The
presence of mild obstructive sleep apnoea was defined as
an AHI ≥5 and <15, moderate obstructive sleep apnoea was
defined as an AHI ≥15 and <30, and severe obstructive
sleep apnoea was defined as an AHI ≥30.26
Medical records were accessed to ascertain key variables,
including maternal age, gravidity, parity, gestational age at
time of study, height, and weight. As body mass index
(BMI) is strongly associated with obstructive sleep apnoea,
pre-pregnancy or early first-trimester BMI was categorised
according to Institute of Medicine recommendations.34 The
women were classified as underweight (BMI <18.5 kg/m2),
normal weight (BMI 18.5–24.9 kg/m2), overweight (BMI
25.0–29.9 kg/m2), or obese (BMI ≥30.0 kg/m2). In addi-
tion, clinical diagnoses and medication status were
recorded. In reporting this study, guidelines from the
Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) group were followed.35
Statistical analysis
Data were double entered into a database and checked for
outliers and normality of the distribution. Analyses were
performed using SPSS 20 (IBM SPSS Statistics, Armonk, NY,
USA). Means and standard deviations (SDs) were provided
for normally distributed data, and medians and interquartile
ranges (IQRs) were provided for non-normally distributed
data. For normally distributed data, between-group compar-
isons of continuous variables were conducted with Student’s
t-tests (hypertension versus no hypertension) and ANOVA
(chronic hypertension versus gestational hypertension versus
pre-eclampsia), where appropriate. Dichotomised variables
were compared with chi-square tests. Non-normally distrib-
uted data were analysed using non-parametric statistics.
P < 0.05 was considered to be statistically significant.
Pooled relative risks were calculated using the Mantel
Haenszel method and confidence intervals were calculated
using the Greenland–Robin variance formula.36
Results
A total of 181 hypertensive pregnant women and 70 healthy
women who were normotensive were invited to participate;
53 women with hypertensive disorders (29%) and 18 women
who were normotensive (26%) agreed. After signing the
consent form, but prior to the overnight study, two women
withdrew (n = 1 hypertensive and n = 1 normotensive) and
one woman who was hypertensive delivered her infant. The
number of women with hypertensive disorders included in
the final analysis was therefore 51, and the number of
women who were normotensive was 16. There were no
demographic differences nor differences in the frequency of
snoring between those who declined participation and those
who participated (data not shown). Overall, among women
with hypertensive disorders at the time of the overnight
study, 59% had chronic hypertension (cHTN), 23% had ges-
tational hypertension (GHTN), and 18% had pre-eclampsia
(Pre-E). Demographic data are shown in Table 1.
In total, in comparison with women who were normo-
tensive, women with hypertensive disorders were signifi-
cantly more likely to report snoring: n = 31 (61%) versus
n = 3 (19%); P = 0.008. After stratification by obesity, the
pooled relative risk for snoring in women with hypertensive
disorders was 3.4 (95% CI 2.7–4.3).
Within the hypertensive group, snoring at least three
nights per week was reported by n = 19 (63%) of the
women with chronic hypertension, n = 7 (58%) of the
women with GHTN, and n = 5 (56%) of the women with
Pre-E. Notably, the majority of women with cHTN (as well
as women who snored but who were normotensive)
reported habitual snoring before pregnancy, whereas those
with GHTN and Pre-E who snored were more likely to
report the onset of snoring during pregnancy rather than
before pregnancy (Table 2). Few women reported that they
stopped breathing at night (‘witnessed apnoea’), with the
exception of GHTN where no woman gave a positive
answer, and only one woman in each of the other groups
answered positively (3% of cHTN, 11% of Pre-E, and 5%
of normotensive).
Results from the evaluation of obstructive sleep apnoea
are shown in Table 2. Women with pre-E as well as those
with cHTN had the highest number of respiratory events
compared with other women, but this did not reach statis-
tical significance. The only statistically significant differ-
ences between groups were found with mean SpO2 and
SpO2 nadir. A subanalysis of just the women with
EEG-based sleep duration measures did not change any of
the findings, and so all analyses used the total sample.
Figure 1A illustrates the proportion of women in each
threshold of apnoea severity. Approximately half of all
women with cHTN and pre-E were found to have
unrecognised obstructive sleep apnoea. One-quarter of
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those with GHTN had obstructive sleep apnoea compared
with one in five women who were normotensive. Of note,
approximately 10% of women with hypertensive disorders
had severe obstructive sleep apnoea (AHI ≥30). Figure 1B
illustrates the proportion of women falling at or below the
thresholds of minimum nocturnal oxygen saturation for
each group. The majority of women with hypertensive dis-
orders had dips in oxygen saturation below 90%; however,
Table 1. Demographic data for the total sample
Normotensive
controls
(n = 16)
Chronic
hypertension
(n = 30)
Gestational
hypertension
(n = 12)
Pre-eclampsia
(n = 9)
Mean age (years) 28.1 (9.2) 33.3 (4.0)* 31.9 (6.8) 30.4 (7.1)
Mean pre-pregnancy BMI (kg/m2) 23.7 (4.8) 41.0 (10.4)*,††,‡ 34.1 (11.2)** 31.1 (9.6)
Obese pre-pregnancy (%) 2 (13%) 27 (90%)*,‡‡ 8 (67%)* 5 (56%)***
BMI at study entry (kg/m2) 28.1 (4.7) 43.6 (9.3)*,††,‡‡ 37.2 (11.3)** 36.0 (8.2)***
Race (%)
White 9 (56%) 15 (50%) 9 (75%) 5 (56%)
African american 3 (19%) 15 (50%) 3 (25%) 3 (33%)
Asian 3 (19%) 0 (0%)*** 0 (0%)*** 0 (0%)***
Biracial 1 (6%) 0 (0%) 0 (0%) 1 (11%)
Gestational age (weeks) 33.8 (3.8) 24.6 (8.1)*,†,‡‡ 33.0 (2.9) 30.1 (4.2)
Gravidity 2.5 (1.9) 3.4 (2.4) 2.5 (1.3) 4.6 (3.9)***
Parity 0.8 (1.1) 1.5 (1.7) 0.5 (0.7)‡‡ 1.9 (1.6)
First pregnancy (%) 6 (38%) 8 (27%) 4 (33%) 3 (33%)
Diabetes mellitus (%) 0 (0%) 5 (17%) 0 (0%) 1 (11%)
Gestational diabetes (%) 0 (0%) 2 (7%) 1 (8%) 0 (0%)
Previous history of GHTN/Pre-E 0 (0%) 8 (27%)*** 1 (8%) 1 (11%)
Smoker (%) 2 (12%) 9 (30%)†† 0 (0%) 1 (11%)
Mean and standard deviations are shown in the table; all continuous data were normally-distributed.
*P < 0.001 compared with controls; **P < 0.01 compared with controls; ***P < 0.05 compared with controls.
†P < 0.001 compared with GHTN; ††P < 0.05 compared with GHTN.
‡P = 0.01 compared with pre-eclampsia; ‡‡P < 0.05 compared with pre-eclampsia.
Table 2. Sleep variables
Normotensive
controls
(n = 16)
Chronic
hypertension
(n = 30)
Gestational
hypertension
(n = 12)
Pre-eclampsia
(n = 9)
P
Chronic snoring (n; %) 3 (19%) 16 (53%) 1 (8%) 2 (22%)
Pregnancy-onset snoring (n; %) 0 (0%) 3 (10%) 6 (50%) 3 (33%)
TST (mins) 378.5 (60.3) 325.0 (134.0) 362.0 (87.0) 342.0 (227.5)
AHI 2.5 (3.3) 4.0 (23.5) 2.0 (5.0) 4.0 (7.0)
OAI 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0)
CAI 0.0 (0.0) 0.0 (0.0) 0.0 (0.1) 0.0 (0.0)
HI 2.5 (3.3) 3.5 (10.3) 1.0 (4.5) 4.0 (6.0)
AHI ≥5 (n; %) 3 (19%) 13 (43%) 3 (25%) 5 (56%)
AHI ≥15 (n; %) 1 (6%) 5 (17%) 2 (17%) 1 (11%)
AHI ≥30 (n; %) 0 (0%) 4 (13%) 1 (8%) 1 (11%)
Mean SpO2 (%) (n; %) 96.0 (1.3) 96.0 (2.0) 97.0 (2.0) 95.0 (3.0) 0.023
SpO2 nadir (%) (n; %) 92.0 (2.3) 89.0 (5.5) 90.0 (10.0) 90.0 (4.0) 0.035
SpO2 nadir ≤80% (n; %) 0 (0%) 3 (10%) 1 (8%) 0 (0%)
AHI, apnoea/hypopnoea index; CAI, central apnoea index; HI, hypopnoea index; IQR, interquartile range; OAI, obstructive apnoea index; SpO2,
oxygen saturation; TST, total sleep time.
Continuous data shown as median and IQR as non-normal distribution. Dichotomous data shown as raw numbers and percentage.
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almost one in four women with pre-E had nocturnal satu-
ration nadirs below 80%.
Comparisons between hypertensive groups
Analyses were then conducted between snoring and
non-snoring women with hypertension. The mean AHI was
significantly higher in hypertensive snoring women com-
pared with hypertensive non-snoring women (19.9  34.1
versus 3.4  3.1, P = 0.013). Mean SpO2 did not differ
between these groups (95.3  1.8 versus 95.7  1.9,
P = 0.40); however, the SpO2 nadir was significantly lower
in women with hypertension and snoring compared with
those with hypertension and no snoring (86.4  6.6 versus
90.2  3.5, P = 0.021). Notably, women with hypertensive
disorders who reported habitual snoring were significantly
more likely than non-snoring women with hypertensive
disorders to have undiagnosed obstructive sleep apnoea
(AHI ≥5; 53 versus 24%, P = 0.03; Table 3). After stratifi-
cation by obesity the pooled relative risk for obstructive
sleep apnoea in snoring women with hypertension com-
pared with non-snoring women with hypertension was 2.0
(95% CI 1.4–2.8). Furthermore, approximately one in four
hypertensive snoring women had moderate to severe
obstructive sleep apnoea, and only the hypertensive, snor-
ing women had oxygen desaturations ≤80%.
Discussion
Main findings
This study demonstrates that a substantial proportion of
hypertensive pregnant women have obstructive sleep apnoea,
and that snoring may be an excellent marker in clinical prac-
tice for this condition. Although non-snoring women with
hypertensive disorders frequently had mild obstructive sleep
apnoea, women who self-identified as snorers had moderate
to severe obstructive sleep apnoea with clinically significant
oxygen desaturation. This suggests that pregnant women
with snoring in the setting of hypertension strongly merit
evaluation for underlying obstructive sleep apnoea.
Interestingly, in women with hypertension, the timing of
snoring onset appeared to be related to hypertension type.
Women who reported chronic snoring were most likely to
have chronic hypertension, whereas those who reported the
onset of snoring during pregnancy were more likely to
have gestational hypertension. This finding strengthens
similar observations from our prospective study, in which
we demonstrated that pregnancy-onset snoring indepen-
dently predicted gestational hypertension.17 In contrast, the
timing of snoring onset was variable for women with
pre-eclampsia.
Strengths and limitations
A major strength of this study is the objective measure of
obstructive sleep apnoea via polysomnography in a rela-
tively large sample of women. We chose ambulatory rather
than laboratory-based polysomnography because of the
inherent difficulties of laboratory-based assessment in preg-
nancy, particularly for high-risk women. Although labora-
tory-based monitoring is the ‘gold standard’, it is not often
an option for pregnant women and frequently barriers are
encountered in clinical practice. Indeed, previous polysom-
nographic studies in pregnancy have smaller sample sizes
than the current study,24,37–42 limiting interpretation when
results are non-significant. Use of ambulatory polysomnog-
raphy allowed women to spend the night in their home,
minimised potential anxiety and discomfort, and still pro-
vided consistent apnoea measures.
In the context of research, home monitoring is widely
used, e.g. in National Institutes of Health (NIH) -funded
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Figure 1. (A) Proportion of women with each threshold of AHI by
hypertensive status. (B) Proportion of women falling at or below
thresholds of minimum nocturnal oxygen saturation by hypertensive
status.
Table 3. Comparison of hypertensive women with and without
snoring
Hypertension
and snoring
(n = 30)
Hypertension
without
snoring
(n = 21)
AHI ≥5 16 (53%)* 5 (24%)
AHI ≥15 8 (27%)** 0%
AHI ≥30 6 (20%)* 0%
SpO2 nadir ≤80% 6 (20%)* 0%
AHI, apnoea/hypopnoea index; SpO2, oxygen saturation.
*P = 0.05; **P = 0.01.
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multicentre epidemiological studies such as the Sleep Heart
Health Study and the Study of Women’s Health Across the
Nation.43,44 The number of respiratory events obtained from
ambulatory monitors is strongly correlated with those
obtained from laboratory-based polysomnography, whether
or not full polysomnography or cardiopulmonary monitor-
ing is used.43,45–47 In a meta-analysis home studies were
found to provide similar diagnostic information to labora-
tory polysomnography, but may underestimate the severity
of obstructive sleep apnoea.48 If so, then our findings may
have underestimated the severity of obstructive sleep apnoea.
An additional strength was the inclusion of women with
chronic hypertension, gestational hypertension, and
pre-eclampsia. This allowed the assessment of differential
patterns of association with obstructive sleep apnoea, for
the first time.
A limitation is that, although we have demonstrated a
clear association between hypertension during pregnancy
and obstructive sleep apnoea, we were unable to determine
causality. We suggest that future studies include a prospec-
tive cohort of women that are recruited in early pregnancy
and followed through the postnatal period to determine the
temporal relationship between hypertension and obstructive
sleep apnoea in this population. In addition, large treat-
ment intervention studies in pregnancy using positive air-
way pressure therapy are also required. Small pilot studies
of positive airway pressure in hypertensive pregnancies are
encouraging, and suggest that maternal blood pressure can
be reduced by treatment of obstructive sleep apnoea;39,49
however, no large, randomised studies exist.
As discussed below, a wealth of information including
randomised clinical trials demonstrates a casual pathway
between obstructive sleep apnoea and hypertension in
non-pregnant adults,50 and similar pathways are likely in
pregnancy.51,52 Caution may be warranted in pregnancy,
however, because of the occurrence of other physiological
changes, as hypertension may promote obstructive sleep
apnoea.53 Secondly, only approximately one-third of
women who were invited to take part actually participated.
It is possible that those who agreed were more likely to
have sleep problems; however, sleep data collected on those
who declined participation demonstrated that this was not
the case. This suggests that our data are unlikely to have
significant bias in this regard.
Interpretation (finding in light of other evidence)
The causal association between snoring/obstructive sleep
apnoea has been reported in multiple epidemiological stud-
ies of non-pregnant adults.54–56 It is well established that
obstructive sleep apnoea affects autonomic function,57–59
and subsequently modifies cardiovascular regulation.60 The
cyclic deoxygenation–reoxygenation during repeated
apnoeic events, as well as sleep fragmentation from arous-
als, contributes to alterations in the autonomic nervous
system. In addition, chronic intermittent hypoxia and exag-
gerated negative intrathoracic pressure swings can provoke
systemic inflammation, oxidative stress, endothelial
dysfunction, atherosclerosis, and hypertension.61,62
In meta-analyses of randomised controlled trials in the non--
pregnant population, positive airway pressure, the first-line
treatment for obstructive sleep apnoea, has been shown to
reduce both daytime and nocturnal blood pressure.13,14
Data from pregnant women suggest that snoring/obstruc-
tive sleep apnoea is associated with gestational hypertension
and pre-eclampsia,15,17,19–22 as well as fetal growth restric-
tion, operative delivery, prematurity, and admission to the
neonatal intensive care unit.15,20,63–65 We previously demon-
strated a clear independent association with pregnancy-onset
snoring and maternal hypertension.17 Moreover, a repeat
polysomnographic study of women 1–2 years following ges-
tational hypertension (as well as healthy controls) has shown
that women with hypertensive disorders experienced a
decrease in the respiratory disturbance index, whereas con-
trols did not.66 The authors suggested that the physiological
effects of pregnancy may have a pathological role in the
development of obstructive sleep apnoea during pregnancy
in women with gestational hypertension.
The mechanisms of sleep disruption that affect cardio-
vascular morbidity in non-pregnant individuals are remark-
ably similar to the biological pathways for pre-eclampsia.
Although the pathogenic process for pre-eclampsia is likely
to originate in the placenta, the pathways include endothe-
lial dysfunction, oxidative stress, and inflammation.51 These
shared mechanistic pathways have been discussed previ-
ously.52 Nonetheless, although the timing of snoring onset
appears to be associated with the timing of hypertension
onset, this could also reflect an association in the opposite
direction: i.e. snoring could be a manifestation of hyperten-
sion or associated oedema. Although this is less likely, the
cross-sectional nature of our study precludes a definitive
answer.
Our findings are consistent with those of Reid et al.24
who studied women with gestational hypertension/
pre-eclampsia and healthy pregnant controls with labora-
tory-based polysomnography; this study also found that
approximately half of women with hypertensive disorders
had undiagnosed obstructive sleep apnoea. No women with
chronic hypertension were included.
In the present study, although half of the women with
hypertensive disorders had unrecognised obstructive sleep
apnoea, those who reported snoring were at particular risk.
These women were exclusively found to have moderate to
severe obstructive sleep apnoea with significantly lower
oxyhaemoglobin nadirs, whereas non-snoring women with
hypertensive disorders had only mild obstructive sleep
apnoea. This suggests that self-report of habitual snoring in
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hypertensive pregnancies may be a useful clinical marker
for moderate to severe obstructive sleep apnoea that can be
easily ascertained in the clinic. Nonetheless, mild obstruc-
tive sleep apnoea may not be benign. In non-pregnant pop-
ulations mild obstructive sleep apnoea is associated with
autonomic alterations and cardiac structural changes.67–69
Data from pregnant women show that airflow limitation in
the absence of obstructive sleep apnoea is frequent in
pre-eclampsia,70 and is reversible with positive airway pres-
sure treatment, with a simultaneous reduction in blood
pressure.49
A previous study of 24-hour ambulatory blood pressure
in 186 hypertensive pregnant women has shown that over
half of women also have nocturnal hypertension,71 and that
this was most prevalent in pre-eclampsia (79%) compared
with gestational or essential hypertension (45%). Of note,
marked augmentation of the haemodynamic response to
obstructive apnoeas is observed in pre-eclampsia.49 In
pre-eclampsia, sleep is associated with adverse haemody-
namic changes, which can be minimised by positive airway
pressure therapy.40 This suggests that continuous fluctua-
tions of blood pressure caused by nocturnal obstructive
events may have relevance to altered blood pressure con-
trol, and this has clinical implications for the monitoring
and treatment of hypertensive pregnant women.
Conclusion
Approximately half of pregnant women with hypertension
may have unrecognised obstructive sleep apnoea. Women
presenting with hypertension during pregnancy who also
report snoring are at particularly high risk for moderate to
severe obstructive sleep apnoea, with clinically significant
oxyhaemoglobin desaturation. Although further studies are
urgently required, including longitudinal as well as treat-
ment intervention studies, our findings support the need
for the obstetric healthcare provider to consider a sleep
evaluation in hypertensive pregnancies, especially when
snoring is present.
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